Page 49 - MI-2-1
P. 49
Microbes & Immunity iPSC-derived NK cell immunotherapy
exhaustion in adaptive and conventional NK cells. J Leukoc cell exhaustion. JCI Insight. 2022;7(15):e50079.
Biol. 2020;108(4):1361-1368.
doi: 10.1172/jci.insight.150079
doi: 10.1002/JLB.4MR0620-091R
92. Vodyanik MA, Slukvin, II. Hematoendothelial
82. Wu Y, Kuang DM, Pan WD, et al. Monocyte/macrophage- differentiation of human embryonic stem cells. Curr Protoc
elicited natural killer cell dysfunction in hepatocellular Cell Biol. 2007;Chapter 23:Unit 23 6.
carcinoma is mediated by CD48/2B4 interactions. doi: 10.1002/0471143030.cb2306s36
Hepatology. 2013;57(3):1107-1116.
93. Lupo KB, Moon JI, Chambers AM, Matosevic S.
doi: 10.1002/hep.26192
Differentiation of natural killer cells from induced
83. Müller-Durovic B, Lanna A, Covre LP, Mills RS, pluripotent stem cells under defined, serum- and feeder-free
Henson SM, Akbar AN. Killer cell lectin-like receptor G1 conditions. Cytotherapy. 2021;23(10):939-952.
inhibits NK cell function through activation of adenosine doi: 10.1016/j.jcyt.2021.05.001
5’-monophosphate-activated protein kinase. J Immunol.
2016;197(7):2891-2899. 94. Euchner J, Sprissler J, Cathomen T, et al. Natural killer cells
generated from human induced pluripotent stem cells mature
doi: 10.4049/jimmunol.1600590
to CD56 bright CD16 NKp80 in-vitro and express KIR2DL2/
+/-
+
84. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, DL3 and KIR3DL1. Front Immunol. 2021;12:640672.
Matsumoto N. Killer cell lectin-like receptor G1 binds three doi: 10.3389/fimmu.2021.640672
members of the classical cadherin family to inhibit NK cell
cytotoxicity. J Exp Med. 2006;203(2):289-295. 95. Feng Q, Zhang MY, Lu SJ. Abstract LB-071: Functional NK
cells generated from human iPS cells with 3D-bioreactor
doi: 10.1084/jem.20051986
for immuno-oncology. Cancer Res. 2019;79(13_
85. Lou C, Wu K, Shi J, Dai Z, Xu Q. N-cadherin protects Supplement):LB-071.
oral cancer cells from NK cell killing in the circulation by doi: 10.1158/1538-7445.Am2019-lb-071
inducing NK cell functional exhaustion via the KLRG1
receptor. J Immunother Cancer. 2022;10(9):e005061. 96. Pende D, Falco M, Vitale M, et al. Killer Ig-like receptors
(KIRs): Their role in NK cell modulation and developments
doi: 10.1136/jitc-2022-005061
leading to their clinical exploitation. Front Immunol.
86. Xu B, Ma R, Russell L, et al. An oncolytic herpesvirus 2019;10:1179.
expressing E-cadherin improves survival in mouse models doi: 10.3389/fimmu.2019.01179
of glioblastoma. Nat Biotechnol. 2018; 37:45-54.
97. Wang W, Erbe AK, Alderson KA, et al. Human NK
doi: 10.1038/nbt.4302
cells maintain licensing status and are subject to killer
87. Zhang B, Zhao W, Li H, et al. Immunoreceptor TIGIT immunoglobulin-like receptor (KIR) and KIR-ligand
inhibits the cytotoxicity of human cytokine-induced inhibition following ex vivo expansion. Cancer Immunol
killer cells by interacting with CD155. Cancer Immunol Immunother. 2016;65(9):1047-1059.
Immunother. 2016;65(3):305-314.
doi: 10.1007/s00262-016-1864-z
doi: 10.1007/s00262-016-1799-4
98. Wu Y, Tian Z, Wei H. Developmental and functional
88. Liu ZY, Deng L, Jia Y, et al. CD155/TIGIT signalling plays control of natural killer cells by cytokines. Front Immunol.
a vital role in the regulation of bone marrow mesenchymal 2017;8:930.
stem cell-induced natural killer-cell exhaustion in multiple doi: 10.3389/fimmu.2017.00930
myeloma. Clin Transl Med. 2022;12(7):e861.
99. Goldenson BH, Zhu H, Wang YM, et al. Umbilical cord
doi: 10.1002/ctm2.861
blood and iPSC-derived natural killer cells demonstrate
89. Sarhan D, Cichocki F, Zhang B, et al. Adaptive NK cells with key differences in cytotoxic activity and KIR profiles. Front
low TIGIT expression are inherently resistant to myeloid- Immunol. 2020;11:561553.
derived suppressor cells. Cancer Res. 2016;76(19):5696-5706.
doi: 10.3389/fimmu.2020.561553
doi: 10.1158/0008-5472.CAN-16-0839
100. Chen AP, Gao P, Ashok P, et al. 323TALEN based
90. Solomon BL, Garrido-Laguna I. TIGIT: A novel gene edited iPSC-derived NK (iNK) cells demonstrate
immunotherapy target moving from bench to bedside. enhanced antitumor activity. J Immunother Cancer.
Cancer Immunol Immunother. 2018;67(11):1659-1667. 2022;10(Suppl 2):A339.
doi: 10.1007/s00262-018-2246-5 doi: 10.1136/jitc-2022-SITC2022.0323
91. Myers JA, Schirm D, Bendzick L, et al. Balanced engagement 101. Kwon D, Moon BK, Han M, Lee TW, Lee JH, Kang KS. Abstract
of activating and inhibitory receptors mitigates human NK 1330: Universal and potent chimeric antigen receptor-
Volume 2 Issue 1 (2025) 41 doi: 10.36922/mi.5653
